Stem Cell Therapy in Thailand Your guide to cost, top specialists & hospitals

Our partner hospitals operate dedicated haematology transplant programmes. The leading JCI-accredited Bangkok hospitals we work with have HEPA-filtered isolation wards, on-site stem cell processing and cryopreservation labs, blood banking services, and intensive care units equipped to manage transplant-related complications.

Our partner haematologists hold board certification and fellowship training in transplant medicine. They manage the full spectrum of autologous, allogeneic, and haploidentical cases. Many trained at established international transplant programmes and bring that depth of experience to clinical decision-making during the complex phases of transplant.

HEPA-filtered isolation, on-site blood banking, stem cell processing labs, and 24-hour haematology coverage are the non-negotiable requirements. Ask about annual transplant volume; higher-volume centres manage complications more effectively. Confirm the centre has experience with your specific transplant type and disease diagnosis.

Engraftment, confirmed by rising neutrophil counts, typically occurs within two to three weeks. Long-term outcomes after allogeneic transplant vary widely with disease type, risk category, and remission status at transplant: survival is more favourable for standard-risk acute leukaemia transplanted in first remission and considerably lower for high-risk or relapsed disease, so a single headline figure can mislead. Autologous transplant for myeloma extends progression-free survival by several years. Overall outcomes continue to improve with advances in conditioning, GVHD prevention, and supportive care. Your haematologist gives figures specific to your diagnosis and risk profile.

Your haematologist discusses expected outcomes based on your diagnosis, disease stage, and chosen transplant type. Key milestones include neutrophil engraftment, platelet recovery, hospital discharge, and progressive immune reconstitution. Disease status is monitored through blood tests, chimerism analysis, and bone marrow biopsies at defined intervals.

Stem cell therapy in Thailand typically costs between $30,000 and $54,000. Autologous transplants are at the lower end, while allogeneic and haploidentical procedures cost more due to donor workup, longer isolation periods, GVHD prevention, and additional supportive care requirements.

The haematologist's fee covers pre-transplant assessment, conditioning oversight, and post-transplant management. Hospital charges include the isolation ward, nursing care, and blood banking. Stem cell collection or donor procurement, conditioning drugs, post-transplant medications, and coordinator support are itemised separately.

Transplant type is the primary driver; autologous requires no donor and involves a shorter stay. Conditioning intensity, isolation duration, transfusion volume, and complication management all affect the total. Unrelated donor search fees through international registries are an additional cost when no family donor is available.

Typical ranges at our partner hospitals:

• Autologous transplant: $30,000–$38,000 using own stem cells, with shorter isolation and no GVHD risk
• Matched allogeneic transplant: $40,000–$48,000 with a sibling or registry donor and a longer stay
• Haploidentical transplant: $45,000–$54,000 with a half-matched donor and PTCy protocol

Final pricing is confirmed after pre-transplant evaluation and treatment planning.

Stem cell therapy in Thailand costs 50 to 70 percent less than equivalent treatment in the US ($90,000–$180,000), Australia (A$75,000–A$150,000), and UK (£66,000–£135,000). For a treatment often costing six figures privately, the savings make transplant financially possible for patients who could not access it at home.

Isolation typically lasts two to four weeks, from conditioning through engraftment. HEPA-filtered rooms, restricted visitors, and strict hygiene protocols protect you while your immune system is absent. You move to a step-down ward once neutrophils reach a safe level, though infection precautions continue.

Most patients are cleared to travel six to ten weeks after the transplant infusion, once engraftment is established, immediate complications are managed, and outpatient follow-up is stable. Your haematologist provides a fitness-to-travel assessment and comprehensive handover documentation for your home team.

Full immune recovery takes three to twelve months.^5,6 You avoid crowded spaces and contact with unwell people during this period. Light walking starts on the ward, moderate exercise builds from around month 3 to 6, and driving usually resumes from around month 2 to 3 once you are off sedating medication and your team clears you. The neutropenic (low-microbial) diet lifts once neutrophils are stably recovered (commonly above 1.0 x10⁹/L) and you are off heavy immunosuppression, with normal eating usually restored by around 6 to 12 months. Vaccinations are given on a new schedule. Your haematologist monitors for chronic GVHD, endocrine changes, and late effects through regular reviews at home.

Yes. Our partner hospitals hold JCI accreditation and run dedicated transplant programmes with the specialist infrastructure required: HEPA filtration, 24-hour haematology nursing, blood banking, stem cell processing labs, and ICU capability. Outcomes are consistent with international published data.

Prevention starts with accurate HLA matching and appropriate conditioning. Post-transplant immunosuppression (calcineurin inhibitors, methotrexate, or cyclophosphamide depending on the protocol) reduces GVHD incidence. When GVHD occurs, it is graded and treated with corticosteroids and, if needed, additional immunosuppressive agents.

Primary graft failure (cells never engraft) occurs in a small percentage of transplants and may require a second infusion, a different donor source, or an alternative treatment strategy. Secondary graft failure, the loss of a graft that had initially taken, can occur weeks after engraftment and is managed the same way. Your haematologist plans for both contingencies during the initial workup. Chimerism testing, measuring the proportion of donor versus host cells, monitors engraftment progress.

Allogeneic transplant carries a real risk of treatment-related (non-relapse) mortality, meaning death from complications such as infection, severe GVHD, or organ toxicity rather than from the cancer. Depending on age, fitness, donor match, and conditioning intensity, this is a real and recognised risk, and it is lower for autologous transplant and for reduced-intensity protocols in carefully selected patients. Your haematologist gives you a figure specific to your case during consent, weighed against the risk of the disease itself.

Plan for six to ten weeks minimum. This covers pre-transplant evaluation, conditioning therapy, the stem cell infusion, isolation during engraftment, step-down ward recovery, and outpatient follow-up before your haematologist clears you to travel home. Some patients require longer stays depending on complications or GVHD management.

Your package covers the haematologist and transplant team, conditioning therapy, stem cell infusion, isolation room and nursing, pre-transplant diagnostics and HLA typing, post-transplant medications and blood products, and coordinator support throughout. Donor search fees, accommodation, and flights are arranged separately.

We strongly encourage bringing a companion for the duration of your stay. The emotional and practical support during isolation and recovery is significant. Your coordinator helps arrange nearby accommodation and facilitates hospital visiting within infection-control protocols. Being accompanied makes a difficult process more bearable.